Roche has been attempting to develop an Alzheimer's drug for some time, and its first attempts with two other anti-amyloid antibodies – crenezumab and gantenerumab – ended in failure.

UCB and Biogen say their first phase 3 trial of systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, with a second planned.